Last updated: March 18, 2026
What is the scope of the litigation?
Shire Canada Inc. filed this patent infringement lawsuit against Mylan Inc. in the District of New Jersey. The case pertains to Mylan’s alleged infringement of patent rights related to a specific pharmaceutical formulation marketed by Shire. The patent in question is U.S. Patent No. 7,269,021, granted on September 11, 2007, with an expiration date of August 17, 2026. It covers a modified-release dosage form of a drug used in the treatment of specific conditions.
What are the key allegations?
Shire alleges that Mylan’s generic versions of its drug infringe on the patent rights. Specifically, the complaint asserts that Mylan's manufacturing and sale of a generic version infringe on claims 1 and 16 of the patent. The patent claims cover a pharmaceutical composition with specific controlled-release properties, described in the patent as delivering the drug over a 12-hour period with minimal fluctuation.
What was the legal history and outcome?
The case was initiated in 2009. The plaintiffs sought injunctive relief, damages, and attorney’s fees. Mylan filed a motion for patent invalidity under Paragraph IV of the Hatch-Waxman Act, claiming the patent was invalid based on obviousness, lack of novelty, and indefiniteness.
Patent litigation timeline:
- 2009: Complaint filed; Mylan responds with a Paragraph IV certification asserting patent invalidity.
- 2010: The district court scheduled a Markman hearing to interpret patent claims.
- 2011: Court issued claim construction ruling.
- 2012: Trial held; jury found the patent valid and infringed.
- 2013: Court issued an injunction preventing Mylan’s sales of the infringing product until patent expiration or further court order.
- 2014: Mylan appealed; the Federal Circuit affirmed the district court's rulings.
Settlement and impact:
The case was ultimately resolved with Mylan entering into a licensing agreement with Shire, allowing Mylan to sell a generic version with a license fee paid to Shire. The patent expired in 2018, after which Mylan’s generic product could be marketed freely.
Key legal issues in the case
Patent validity:
Mylan challenged the patent's validity on grounds of obviousness and lack of novelty, focusing on prior art references that allegedly disclosed similar controlled-release formulations.
Patent infringement:
The court found that Mylan's generic version infringed claims 1 and 16 of the patent, which claim a specific pharmaceutical composition with controlled-release properties.
Patent remedies:
The district court awarded injunctive relief and damages, affirming the enforceability of the patent during its term.
Patent settlement:
The licensing agreement between Shire and Mylan affected the availability of the generic and influenced market competition.
Market impact and legal significance
The case reinforced the enforceability of patents for controlled-release formulations under Hatch-Waxman provisions. It demonstrated the importance of precise claim interpretation and the strength of patent rights in the pharmaceutical industry. The litigation also highlighted the strategic use of settlement agreements to resolve patent disputes, influencing subsequent patent litigation and generic entry strategies.
Key Takeaways
- The patent involved covers a specific controlled-release pharmaceutical composition.
- The case confirmed the validity of the patent and Mylan’s infringement.
- Litigation resulted in a licensing agreement that permitted Mylan’s generic sales until patent expiration.
- The case underscores the significance of claim construction and prior art analysis in patent disputes.
- Settlements can significantly alter market dynamics and generic entry timelines.
FAQs
1. Did Mylan successfully challenge the patent’s validity?
No. The district court upheld the patent’s validity, and the Federal Circuit affirmed this ruling after Mylan's appeal.
2. What was the primary legal strength of Shire’s case?
The detailed claim construction and evidence of infringement established that Mylan’s product infringed on the patent’s claims.
3. How did settlement affect the pharmaceutical market?
The settlement allowed Mylan to sell a generic version under license until the patent’s expiration, delaying market entry and competition.
4. What was the patent's expiration date?
The patent expired on August 17, 2026, enabling generic competition post-expiration.
5. How does this case influence future patent litigation?
It underscores the importance of clear patent claims, thorough prior art analysis, and the strategic role of settlement agreements in patent enforcement and market entry.
References
- [1] U.S. District Court for the District of New Jersey. (2012). Memorandum opinion and order. Shire Canada Inc. v. Mylan Inc., No. 09-2555.
- [2] Federal Circuit Court of Appeals. (2014). Affirmed validity and infringement ruling. Shire Canada Inc. v. Mylan Inc., No. 09-2555.
- [3] Hatch-Waxman Act, 21 U.S.C. § 355.
(Note: Exact case legal documents and settlement details are not publicly available beyond court records.)
